PE20070414A1 - Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol) - Google Patents

Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol)

Info

Publication number
PE20070414A1
PE20070414A1 PE2006000926A PE2006000926A PE20070414A1 PE 20070414 A1 PE20070414 A1 PE 20070414A1 PE 2006000926 A PE2006000926 A PE 2006000926A PE 2006000926 A PE2006000926 A PE 2006000926A PE 20070414 A1 PE20070414 A1 PE 20070414A1
Authority
PE
Peru
Prior art keywords
hydroxy
water
formulation
carmoterol
quinolinone
Prior art date
Application number
PE2006000926A
Other languages
English (en)
Inventor
Raschini Annamaria Soliani
Alessandro Bodria
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20070414A1 publication Critical patent/PE20070414A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA LIQUIDA QUE COMPRENDE: A) UNA SAL HIDROSOLUBLE DE 8-HIDROXI-5-[(1R)-1-HIDROXI-2-[[(1R)-2-(4-METOXIFENIL)-1-METILETIL]AMINO]ETIL]-2(1H)-QUINOLINONA (CARMOTEROL) TAL COMO CLORHIDRATO QUE SE ENCUENTRA EN UNA CANTIDAD DE 0,0005 A 0,001% P/V DE LA FORMULACION; B) UN SOLVENTE TAL COMO AGUA O UNA SOLUCION ACUOSA QUE CONTIENE UN 50% V/V DE AGUA Y UN COSOLVENTE MISCIBLE EN AGUA TAL COMO PROPILENGLICOL; C) UN AGENTE AMORTIGUADOR TAL COMO EL PAR ACIDO CITRICO/CITRATO DE SODIO O EL PAR ACIDO CITRICO/FOSFATO DISODICO QUE SE ENCUENTRA EN UNA CONCENTRACION DE 2mM A 10mM EN LA FORMULACION; Y D) UN AGENTE PARA AJUSTAR LA TONICIDAD TAL COMO CLORURO DE SODIO. DICHA FORMULACION SE ADMINISTRA POR NEBULIZACION Y TIENE UN pH DE 4,0 A 5,0 SIENDO UTIL EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2006000926A 2005-08-01 2006-07-31 Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol) PE20070414A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05016664 2005-08-01

Publications (1)

Publication Number Publication Date
PE20070414A1 true PE20070414A1 (es) 2007-05-11

Family

ID=37564044

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000926A PE20070414A1 (es) 2005-08-01 2006-07-31 Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol)

Country Status (14)

Country Link
US (1) US20070065366A1 (es)
EP (1) EP1915129B1 (es)
JP (1) JP2009502997A (es)
CN (1) CN101198313A (es)
AR (1) AR055363A1 (es)
AT (1) ATE446739T1 (es)
AU (1) AU2006275137A1 (es)
CA (1) CA2617286A1 (es)
DE (1) DE602006010088D1 (es)
EA (1) EA013351B1 (es)
ES (1) ES2332290T3 (es)
PE (1) PE20070414A1 (es)
TW (1) TW200735870A (es)
WO (1) WO2007014673A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2132179B1 (en) * 2007-02-28 2012-08-08 Cipla Limited Process for preparing isomers of carmoterol
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
AR081026A1 (es) * 2010-05-10 2012-05-30 Gilead Sciences Inc Analogos de quinolina y su uso en el tratamiento de enfermedades respiratorias
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
WO2013063287A1 (en) * 2011-10-25 2013-05-02 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
AU2013271436B2 (en) 2012-06-07 2017-02-16 Corning Incorporated Delamination resistant glass containers
US10273048B2 (en) 2012-06-07 2019-04-30 Corning Incorporated Delamination resistant glass containers with heat-tolerant coatings
US9034442B2 (en) 2012-11-30 2015-05-19 Corning Incorporated Strengthened borosilicate glass containers with improved damage tolerance
US10117806B2 (en) 2012-11-30 2018-11-06 Corning Incorporated Strengthened glass containers resistant to delamination and damage
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN107224427A (zh) * 2013-07-01 2017-10-03 成都苑东生物制药股份有限公司 一种格隆溴铵注射液组合物及其制备方法
MX2017002898A (es) 2014-09-05 2017-10-11 Corning Inc Artículos de vidrio y métodos para mejorar la confiabilidad de artículos de vidrio.
CN107001102A (zh) 2014-11-26 2017-08-01 康宁股份有限公司 用于生产强化且耐用玻璃容器的方法
CN110376313B (zh) * 2019-08-20 2022-06-07 广州健康元呼吸药物工程技术有限公司 一种检测富马酸福莫特罗或其相关制剂中杂质的方法
CN114452250A (zh) * 2021-12-14 2022-05-10 澳美制药(苏州)有限公司 盐酸丙卡特罗口服液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US20030215396A1 (en) * 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
CA2534120C (en) * 2003-07-31 2012-09-11 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising anticholinergics and a betamimetic
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form

Also Published As

Publication number Publication date
AR055363A1 (es) 2007-08-22
WO2007014673A3 (en) 2007-07-19
EP1915129A2 (en) 2008-04-30
EA200800142A1 (ru) 2008-08-29
JP2009502997A (ja) 2009-01-29
CN101198313A (zh) 2008-06-11
EP1915129B1 (en) 2009-10-28
DE602006010088D1 (de) 2009-12-10
AU2006275137A1 (en) 2007-02-08
US20070065366A1 (en) 2007-03-22
WO2007014673A2 (en) 2007-02-08
ATE446739T1 (de) 2009-11-15
EA013351B1 (ru) 2010-04-30
TW200735870A (en) 2007-10-01
CA2617286A1 (en) 2007-02-08
ES2332290T3 (es) 2010-02-01

Similar Documents

Publication Publication Date Title
PE20070414A1 (es) Formulaciones farmaceuticas que comprenden 8-hidroxi-5-[(1r)-1-hidroxi-2-[[(1r)-2-(4-metoxifenil)-1-metiletil]amino]etil]-2(1h)-quinolinona (carmoterol)
ES2572973T3 (es) Composiciones que contienen formoterol y un esteroide para administración a los pulmones
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
BRPI0415470A (pt) preparação em aerossol aquosa
CA2382886A1 (en) Benzamide formulation with histone deacetylase inhibitor activity
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
RU2361593C3 (ru) Комбинация азеластина и стероидов
JP2008522981A5 (es)
ATE311174T1 (de) Wässrige zusammenstellungen die corticosteroide enthalten zur nasalen oder pulmonalen verabreichung
EA200501001A1 (ru) Фармацевтический состав с нерастворимым активным агентом
EA200501105A1 (ru) Фармацевтическая композиция
JP2016513690A (ja) シルデナフィルおよび他のホスホジエステラーゼ５阻害剤の経皮送達
MX2009003002A (es) Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.
JP2013513612A5 (es)
PE20070353A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
RU2008110644A (ru) Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
ES2312921T3 (es) Disolucion acuosa concentrada de ambroxol.
EA023535B9 (ru) Композиция водного радиопротекторного фармацевтического раствора и способ предотвращения, снижения или исключения эффектов ионизирующей радиации
AR043536A1 (es) Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico
PE20130180A1 (es) Soluciones farmaceuticas orales que comprenden telbivudina
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
JP2002080314A (ja) 防腐剤
AU2006341592A1 (en) Intramuscular antiviral treatments

Legal Events

Date Code Title Description
FC Refusal